ABCC4 Knockout Jurkat Polyclonal Cells represent a CRISPR/Cas9-mediated gene-disrupted polyclonal cell population derived from the Jurkat human T lymphocyte leukemia cell line, targeting the ABCC4 (ATP-binding cassette subfamily C member 4) transporter gene. This knockout model abolishes the ATP-dependent efflux of cyclic nucleotides, prostaglandins, and xenobiotic substrates, providing a loss-of-function platform for investigating intracellular signaling dynamics and drug transport mechanisms. The polyclonal format ensures a heterogeneous yet representative knockout population suitable for bulk cellular assays that do not require clonal homogeneity.
Jurkat cells are an immortalized line originally derived from the peripheral blood of a patient with acute T cell leukemia. They serve as a widely used model for studying T cell receptor signaling, leukemia biology, and lymphocytic activation. Their robust growth and malignant origin make them amenable to genetic manipulation and high-throughput analyses. In the ABCC4 knockout context, the Jurkat background allows interrogation of cyclic nucleotide regulation in leukemic T cells, where altered cAMP/cGMP flux may influence proliferation, apoptosis, and drug sensitivity.
ABCC4 encodes a broad-specificity transporter that actively exports cAMP, cGMP, and other signaling molecules. Knockout leads to accumulation of intracellular cAMP and cGMP, potentiating protein kinase A (PKA) and protein kinase G (PKG) activities. PKA phosphorylates CREB, modulating gene expression. Upstream, ABCC4 is regulated by NRF2 and cytokines such as IL-2, and it interacts with PDZK1. The receptor-independent adenylyl cyclase (ADCY)?CcAMP?CPKA?CCREB axis and phosphodiesterases (PDEs) all converge on ABCC4 as a key modulator of cyclic nucleotide homeostasis.
In Jurkat cells, ABCC4-mediated efflux affects T cell receptor signaling intensity. Elevated cAMP typically suppresses T cell activation, while increased cGMP may promote it; thus, ABCC4 knockout can shift the balance between proliferative and inhibitory signals. This model is particularly relevant for studying drug resistance in leukemia, as ABCC4 overexpression reduces chemosensitivity to agents like methotrexate. Additionally, ABCC4 transports prostaglandins and urate, linking its disruption to inflammatory diseases and gout. The knockout enables dissection of how cyclic nucleotide compartmentalization governs leukemic cell fate and cytokine secretion.
Researchers can employ these cells in various functional assays. Intracellular cAMP and cGMP levels are measured by ELISA to quantify transporter activity. Flow cytometry with calcein-AM assesses drug efflux capacity. Western blotting for phospho-PKA substrates and quantitative PCR for downstream targets reveal signaling changes. MTT assays evaluate altered drug sensitivity profiles. Applications also include identification of new ABCC4 substrates and screening of transport inhibitors. These cells are a versatile tool for transport biology, leukemia research, and pharmacology. For further technical information, contact Ascent Research.
